An observational study in Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension and Dyslipidemia, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Atherosclerosis with a site in Netherlands — 15 open to participants now, 24 under way, 9 of them phase 3. Atherosclerosis · Netherlands.
Among the 102 studies in Atherosclerosis with a site in Netherlands, this one is the 12th largest by planned enrollment of the 30 observational ones that give a count, is one of 5 that started in 2026, is one of 30 observational ones, reaches primary completion later than 14 of the 23 other live ones, and was the 97th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →15 of the 102 studies in Atherosclerosis with a site in Netherlands are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Netherlands, United States, Australia and 4 more countries
Ages 45–80
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Sites in Netherlands, France, Italy and 1 more country
Ages 12+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Eli Lilly and Company · Sites in Netherlands, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 23 · Phase 3 26 · Phase 4 7
First in 2000; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 274 across the 72 interventional studies, 247 across the 30 observational. Of the 68 that completed or were terminated, 27 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 102 have an industry lead sponsor. The 10 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 8 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Atherosclerosis with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT06995183E.S.stroesHeart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening | 2026-12-31 |
| NCT06785974Erasmus Medical CenterStatins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 102 studies in Atherosclerosis with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM). Participants will receive this care as part of routine clinical practice. In addition to standard follow-up, participants will complete questionnaires on quality of life, medication adherence, system usability, and patient satisfaction.
CVRM is essential for patients at increased risk of cardiovascular disease (CVD) as well as for those with established atherosclerotic cardiovascular disease (ASCVD). Monitoring blood pressure and lipid profiles is crucial to achieving guideline-recommended targets. However, many patients fail to reach these targets despite the availability of effective therapies, resulting in an increased risk of recurrent events. Meanwhile, the burden of CVD continues to rise, creating significant pressure on healthcare systems.
A digital care pathway may improve therapy adherence and outcomes by enabling personalized, data-driven care. This study evaluates the effectiveness of a nurse-led, telemonitoring pathway for CVRM in routine practice, where patients measure their blood pressure and LDL-c levels at home. The study aims to improve risk stratification, support earlier intervention, and optimize lipid and blood pressure control, ultimately leading to better patient outcomes.
All patients enrolled in the digital CVRM program will be invited to participate in this registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients on-target for LDL-c
Proportion of patients achieving guideline-recommended LDL-c targets
Time frame: Baseline and 1 year
Mean LDL-c
The mean of LDL-c values in mmol/L, measured at-home
Time frame: Baseline and 1 year follow-up
Number of patients achieving blood pressure control
Proportion of patients achieving guideline-recommended blood pressure targets
Time frame: Baseline and 1 year
Change in home-measured blood pressure values
Change in blood pressure values measured at home with telemonitoring in mmHg
Time frame: Baseline and 1 year
Number of medication changes
Changes in lipid-lowering and antihypertensive medications, defined as change in dose and change in medication type
Time frame: 1 year
5-item Medication Adherence Report Scale (MARS-5)
5 questions about medication adherence, with higher scores indicating better adherence
Time frame: Baseline and 1 year
Visual Analog Scale (VAS) for medication adherence
The scale ranges from 0% to 100%, with higher scores indicating better medication adherence
Time frame: Baseline and 1 year
Quality of life (QoL)
Using the EuroQoL-5D questionnaire
Time frame: Baseline and 1 year
Telehealth Usability Questionnaire (TUQ)
18 questions on patient satisfaction and usability, with higher scores indicating better satisfaction
Time frame: Baseline and 1 year
Hospitalization
Unplanned cardiovascular (re)hospitalization
Time frame: 12 and 24 months
MACE
Cardiovascular death, myocardial infarction, any documented stroke (ischemic or hemorrhagic), ischemia-driven revascularization
Time frame: 12 and 24 months
All-cause mortality
Total number of deaths from any cause
Time frame: 12 and 24 months
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's planned 24 months is below that.
Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Oct 2025 → Mar 2026, primary completion Oct 2027 → Mar 2028 and completion Oct 2030 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →